Hemostats Market

7500+ companies worldwide approach us every year for their revenue growth initiatives

Global top 2000 strategist rely on us for their growth strategies.

80% of fortune 2000 companies rely on our research to identify new revenue sources.

30000 High Growth Opportunities

95% renewal rate

KNOW MORE

Hemostats Market by Type (Thrombin, Oxidized Regenerated Cellulose, Combination, Gelatin, Collagen), Formulation (Matrix & Gel, Sheet & Pad, Sponge, Powder), Application (Orthopedic, Neurological, Cardiovascular Surgery), Region - Global Forecast to 2028

FREE BROCHURE FREE SAMPLE REPORT

Report Code: MD 4093 Oct, 2023, by marketsandmarkets.com

The global hemostats market in terms of revenue was estimated to be worth $2.7 billion in 2023 and is poised to reach $3.7 billion by 2028, growing at a CAGR of 6.7% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Globally, the growing number of accidents has increased the number of surgeries that involve long operating hours. One of the major reasons for blood loss in surgery and trauma patients is the ineffective use of traditional wound closure products, such as sutures, staples, and other hemostatic agents. This, in turn, has increased the need for effective blood loss management products such as hemostats during surgical procedure.

Attractive Opportunities in the Hemostats Market

Hemostats Market

To know about the assumptions considered for the study, Request for Free Sample Report

Hemostats Market

Hemostats Market Dynamics

DRIVER: Growing volume of surgical procedures performed

Common age-related diseases and conditions include arthritis, osteoporosis, lumbar spinal stenosis (LSS), gastroesophageal reflux disease (GERD), and benign prostatic hyperplasia (BPH). These conditions often necessitate surgery to alleviate pain and improve joint function. Patients with arthritis and osteoporosis may have weakened bones and fragile blood vessels, increasing the risk of intraoperative bleeding during knee replacement surgery. Hemostatic agents are crucial in controlling bleeding effectively to prevent complications like hematoma formation and prolonged surgery times.

RESTRAINT: Side effects and allergic reactions associated with hemostats

Poor-quality products are the primary cause of side effects and allergic reactions associated with hemostats. Poor-quality products cause infections, which not only increase the recovery time and, in some cases, may even result in death. Excessive fibrosis and prolonged fixation of a tendon have been reported when absorbable gelatin-based sponges were used in severed tendon repair. Poor-quality products can have a negative impact on the end-user perception of the safety of hemostats and, in turn, affect their adoption in treatment procedures, which also increases the need for alternative products.

OPPORTUNITY: Growth opportunities in emerging economies

Emerging countries across the Asia Pacific, Latin America, and the Middle East & Africa offer significant growth opportunities to major market players operating in the market. This can be attributed to the healthcare infrastructural improvements in these countries, the growing patient population, and the rising healthcare expenditure.

Moreover, the disposable income of populations in developing and emerging countries is on the rise. This increase is another key indicator of expanding access to healthcare. With rising disposable incomes and the increasing medical needs of the middle-class population, hemostats manufacturers are compelled to devise new strategies to meet this demand. Currently, emerging markets are underpenetrated by major players, which indicates a huge untapped market potential.

CHALLENGE: Dearth of skilled personnel for effective use of hemostats

Skilled professionals are required to handle hemostats as the improper closure of arteries after surgical procedures may lead to continuous bleeding or cause ischemia. Some devices even require several steps in sequence while using them. Currently, the lack of skilled surgeons, both in developed and developing economies, is one of the major factors limiting the adoption of these products. The technology landscape and application areas of hemostats are changing rapidly, owing to technological advancements in this field. This necessitates physicians and other healthcare providers to acquire the necessary skills to apply advanced hemostats.

Hemostats Ecosystem/Market Map

Hemostats Market Ecosystem

Oxidized regenerated cellulose-based hemostats segment accounted for the largest share of the hemostats industry in 2022, by type.

The hemostats market is categorized into oxidized regenerated cellulose-based hemostats, thrombin-based hemostats, combination hemostats, gelatin-based hemostats, collagen-based hemostats, and other hemostats, based on type. The oxidized regenerated cellulose-based hemostats segment emerged as the dominant force in the market in 2022. Biocompatibility is a critical consideration in medical products, and ORC-based hemostatic agents are known for their excellent safety profile. ORC-based products are biocompatible, which means they are well-tolerated by the body and typically do not cause adverse reactions or tissue irritation. This quality is crucial in surgical applications, where patient safety is paramount.

Matrix & gel hemostats segment accounted for the largest share in the hemostats industry in 2022, by formulation.

The global hemostats market is categorized into matrix & gel hemostats, sheet & pad hemostats, sponge hemostats, and powder hemostats based on formulation. In 2022, the matrix & gel hemostats segment held the largest share in the market. The substantial market share of matrix & gel hemostats segment can be attributed to the advantages offered by these hemostats, such as their user-friendly application, their economical nature, and biocompatibility.

Orthopedic surgery segment accounted for the largest share in the hemostats industry in 2022, by application.

The hemostats market has been segmented into orthopedic surgery, general surgery, neurological surgery, cardiovascular surgery, thoracic surgery, gynecological surgery, reconstructive surgery, and other surgical applications, based on application. In 2022, the orthopedic surgery segment accounted for the largest share of the market. The growing prevalence of lifestyle disorders, such as arthritis, osteoporosis, and obesity (leading to orthopedic problems), is a major factor responsible for the growing number of orthopedic surgeries performed globally. The increasing geriatric population further contributes to the increased incidence of target disorders globally. The increasing incidence of sports injuries further supports the uptake of hemostats.

North America accounted for the largest share of the hemostats industry in 2022.

The hemostats market is segmented into five major regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2022, North America emerged as the leading contributor, claiming the largest portion of the market share in the hemostats industry. The region has a robust infrastructure for R&D. Also, North America houses several major companies operating in the hemostats sector. These companies have significant expertise, resources, and established distribution networks, which contribute to the region's market dominance. Also, the high burden of chronic conditions on regional healthcare systems is another major driver for market growth. In line with this, the growing volume of orthopedic, bariatric, hernia repair, cardiothoracic, and neurological surgical procedures performed in the region has resulted in the increased demand for hemostats.

Hemostats Market by Region

To know about the assumptions considered for the study, download the pdf brochure

The major players in this market are Johnson & Johnson (US), Baxter International (US), Pfizer Inc. (US), B. Braun SE (Germany), and Becton, Dickinson and Company (US). The market leadership of these players stems from their comprehensive product portfolios and expansive global footprint. These dominant market players possess several advantages, including strong marketing and distribution networks, substantial research and development budgets, and well-established brand recognition.

Scope of the Hemostats Industry:

Report Metric	Details
Market Revenue in 2023	$2.7 billion
Estimated Value by 2028	$3.7 billion
Revenue Rate	Poised to grow at a CAGR of 6.7%
Market Driver	Growing volume of surgical procedures performed
Market Opportunity	Growth opportunities in emerging economies

This report categorizes the hemostats market to forecast revenue and analyze trends in each of the following submarkets:

By Type

Thrombin-based Hemostats
Oxidized Regenerated Cellulose-based Hemostats
Combination Hemostats
Gelatin-based Hemostats
Collagen-based Hemostats
Other Hemostats

By Formulation

Matrix & Gel Hemostats
Sheet & Pad Hemostats
Sponge Hemostats
Powder Hemostats

By Application

Orthopedic Surgery
General Surgery
Neurological Surgery
Cardiovascular Surgery
Reconstructive Surgery
Gynecological Surgery
Other Surgical Applications

By Region

North America
- US
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Switzerland
- Belgium
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- Singapore
- New Zealand
- South Korea
- Indonesia
- Malaysia
- Rest of Asia Pacific
Latin America
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa

Recent Developments of Hemostats Industry

In August 2023, Teleflex Incorporated (US) received US FDA clearance for the expanded indication for QuikClot Control+ in cardiac surgical procedures.
In July 2023, Baxter International (US) launched its PERCLOT Absorbable Hemostatic Powder in the US. This will allow the company to provide surgeons with a full range of active and passive hemostatic products for bleeding control, helping to optimize care for patients.
In December 2020, Teleflex (US) acquired Z-Medica, LLC (US), a medical device company that manufactures and sells hemostatic (hemorrhage control) products.
In March 2020, Ethicon announced the strategic regional launch of the SURGICEL Powder Absorbable Hemostat in Australia, New Zealand, and Thailand.
In December 2019, Advanced Medical Solutions Group (UK) acquired Biomatlante (France), a well-established international developer and manufacturer of innovative surgical biomaterial technologies.

Frequently Asked Questions (FAQ):

What is the projected market revenue value of the global hemostats market?

The global hemostats market boasts a total revenue value of $3.7 billion by 2028.

What is the estimated growth rate (CAGR) of the global hemostats market?

The global hemostats market has an estimated compound annual growth rate (CAGR) of 6.7% and a revenue size in the region of $2.7 billion in 2023.

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 21)

1.1 STUDY OBJECTIVES

1.2 MARKET DEFINITION

1.2.1 INCLUSIONS & EXCLUSIONS

1.3 STUDY SCOPE

1.3.1 HEMOSTATS MARKET

1.3.2 GEOGRAPHIC SCOPE

1.3.3 YEARS CONSIDERED

1.4 CURRENCY

1.5 LIMITATIONS

1.6 STAKEHOLDERS

1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 26)

2.1 RESEARCH DATA

2.2 RESEARCH APPROACH

FIGURE 1 HEMOSTATS MARKET: RESEARCH DESIGN METHODOLOGY

2.2.1 SECONDARY DATA

2.2.1.1 Key data from secondary sources

2.2.2 PRIMARY DATA

2.2.2.1 Primary sources

2.2.2.2 Key data from primary sources

2.2.2.3 Key industry insights

2.2.2.4 Breakdown of primary interviews

FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS

FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION

2.3 MARKET SIZE ESTIMATION

2.3.1 BOTTOM-UP APPROACH

2.3.1.1 Approach 1: Company revenue estimation approach

FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH

2.3.1.2 Approach 2: Presentations of companies and primary interviews

2.3.1.3 Growth forecast

2.3.1.4 CAGR projections

FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS

2.3.2 TOP-DOWN APPROACH

FIGURE 6 HEMOSTATS INDUSTRY: TOP-DOWN APPROACH

2.4 MARKET BREAKDOWN AND DATA TRIANGULATION

FIGURE 7 DATA TRIANGULATION METHODOLOGY

2.5 MARKET SHARE ANALYSIS

2.6 STUDY ASSUMPTIONS

2.7 GROWTH RATE ASSUMPTIONS

2.8 RISK ASSESSMENT

2.8.1 RISK ASSESSMENT: HEMOSTATS MARKET

2.9 RECESSION IMPACT

3 EXECUTIVE SUMMARY (Page No. - 39)

FIGURE 8 HEMOSTATS MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)

FIGURE 9 HEMOSTATS INDUSTRY, BY FORMULATION, 2023 VS. 2028 (USD MILLION)

FIGURE 10 MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)

FIGURE 11 MARKET, BY REGION, 2023 VS. 2028 (USD MILLION)

4 PREMIUM INSIGHTS (Page No. - 42)

4.1 HEMOSTATS MARKET OVERVIEW

FIGURE 12 GROWING NEED TO MANAGE BLOOD LOSS IN PATIENTS DURING SURGICAL PROCEDURES TO DRIVE MARKET GROWTH

4.2 HEMOSTATS INDUSTRY SHARE, BY TYPE, 2023 VS. 2028

FIGURE 13 OXIDIZED REGENERATED CELLULOSE-BASED HEMOSTATS TO CONTINUE TO DOMINATE MARKET IN 2028

4.3 MARKET SHARE, BY FORMULATION, 2023 VS. 2028

FIGURE 14 MATRIX & GEL HEMOSTATS SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE DURING FORECAST PERIOD

4.4 MARKET SHARE, BY APPLICATION, 2023 VS. 2028

FIGURE 15 ORTHOPEDIC SURGERY SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD

4.5 MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

FIGURE 16 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE IN MARKET DURING FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 45)

5.1 INTRODUCTION

5.2 MARKET DYNAMICS

FIGURE 17 HEMOSTATS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES

5.2.1 DRIVERS

5.2.1.1 Growing volume of surgical procedures performed

TABLE 1 TOTAL NUMBER OF KNEE REPLACEMENTS, 2021

TABLE 2 TOTAL NUMBER OF CORONARY ARTERY BYPASS GRAFT PROCEDURES, 2021

5.2.1.2 Rising focus on R&D

5.2.1.3 Rising focus on effective blood loss management in patients during surgeries

5.2.2 RESTRAINTS

5.2.2.1 Side effects and allergic reactions associated with hemostats

5.2.3 OPPORTUNITIES

5.2.3.1 Growth opportunities in emerging economies

TABLE 3 COST OF SURGICAL PROCEDURES: US VS. INDIA (USD)

5.2.3.2 Growing number of hospitals

5.2.4 CHALLENGES

5.2.4.1 Stringent regulatory framework

5.2.4.2 Dearth of skilled personnel for effective use of hemostats

5.2.4.3 High cost of hemostats

5.3 PRICING ANALYSIS

5.3.1 INDICATIVE PRICING MODEL ANALYSIS OF MARKET PLAYERS

TABLE 4 INDICATIVE PRICING FOR HEMOSTATS

5.3.2 AVERAGE SELLING PRICE OF HEMOSTATS, BY REGION

TABLE 5 AVERAGE SELLING PRICE OF HEMOSTATS

5.4 VALUE CHAIN ANALYSIS

FIGURE 18 VALUE CHAIN ANALYSIS OF HEMOSTATS INDUSTRY: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES

5.5 SUPPLY CHAIN ANALYSIS

FIGURE 19 MARKET: SUPPLY CHAIN ANALYSIS

5.6 PATENT ANALYSIS

FIGURE 20 PATENT ANALYSIS FOR HEMOSTATS (JANUARY 2013–DECEMBER 2022)

5.6.1 LIST OF MAJOR PATENTS

5.7 TRADE ANALYSIS

5.7.1 TRADE ANALYSIS FOR HEMOSTATS

TABLE 6 IMPORT DATA FOR HEMOSTATS, BY COUNTRY, 2018–2022 (USD MILLION)

TABLE 7 EXPORT DATA FOR HEMOSTATS, BY COUNTRY, 2018–2022 (USD MILLION)

5.8 ECOSYSTEM ANALYSIS

FIGURE 21 MARKET: ECOSYSTEM ANALYSIS

5.8.1 MARKET: ROLE IN ECOSYSTEM

5.9 PORTER’S FIVE FORCES ANALYSIS

TABLE 8 MARKET: PORTER’S FIVE FORCES ANALYSIS

5.9.1 THREAT OF NEW ENTRANTS

5.9.2 THREAT OF SUBSTITUTES

5.9.3 BARGAINING POWER OF SUPPLIERS

5.9.4 BARGAINING POWER OF BUYERS

5.9.5 INTENSITY OF COMPETITIVE RIVALRY

5.10 REGULATORY LANDSCAPE

TABLE 9 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 10 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 11 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 12 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

5.10.1 NORTH AMERICA

5.10.1.1 US

TABLE 13 CLASSIFICATION OF MEDICAL DEVICES BY US FDA

FIGURE 22 PREMARKET NOTIFICATION: 510(K) APPROVAL FOR MEDICAL DEVICES

5.10.1.2 Canada

FIGURE 23 APPROVAL PROCESS FOR CLASS III MEDICAL DEVICES IN CANADA

5.10.2 EUROPE

FIGURE 24 CE APPROVAL PROCESS IN EUROPE FOR HEMOSTATS

5.10.3 ASIA PACIFIC

5.10.3.1 Japan

TABLE 14 CLASSIFICATION OF MEDICAL DEVICES AND REVIEWING BODY IN JAPAN

5.10.3.2 China

TABLE 15 NMPA MEDICAL DEVICES CLASSIFICATION

5.10.3.3 India

5.11 TECHNOLOGY ANALYSIS

5.12 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES

FIGURE 25 REVENUE SHIFT IN MARKET

6 HEMOSTATS MARKET, BY TYPE (Page No. - 69)

6.1 INTRODUCTION

TABLE 16 HEMOSTATS INDUSTRY, BY TYPE, 2018–2021 (USD MILLION)

TABLE 17 MARKET, BY TYPE, 2022–2028 (USD MILLION)

6.2 PRIMARY NOTES

6.2.1 KEY PRIMARY INSIGHTS

6.3 OXIDIZED REGENERATED CELLULOSE-BASED HEMOSTATS

6.3.1 GROWING AVAILABILITY OF ORC-BASED HEMOSTATIC AGENTS ACROSS UNTAPPED MARKETS TO DRIVE GROWTH

TABLE 18 MAJOR PRODUCTS IN OXIDIZED REGENERATED CELLULOSE-BASED MARKET

TABLE 19 OXIDIZED REGENERATED CELLULOSE-BASED MARKET, BY REGION, 2018–2021 (USD MILLION)

TABLE 20 OXIDIZED REGENERATED CELLULOSE-BASED MARKET, BY REGION, 2022–2028 (USD MILLION)

6.4 THROMBIN-BASED HEMOSTATS

6.4.1 DEVELOPMENTS IN RECOMBINANT THROMBIN PRODUCTS TO SUPPORT GROWTH

TABLE 21 MAJOR PRODUCTS IN THROMBIN-BASED MARKET

TABLE 22 THROMBIN-BASED MARKET, BY REGION, 2018–2021 (USD MILLION)

TABLE 23 THROMBIN-BASED MARKET, BY REGION, 2022–2028 (USD MILLION)

6.5 COMBINATION HEMOSTATS

6.5.1 ADVANCEMENTS IN COMBINATION MATERIALS TO PROPEL MARKET GROWTH

TABLE 24 MAJOR PRODUCTS IN COMBINATION MARKET

TABLE 25 COMBINATION MARKET, BY REGION, 2018–2021 (USD MILLION)

TABLE 26 COMBINATION MARKET, BY REGION, 2022–2028 (USD MILLION)

6.6 GELATIN-BASED HEMOSTATS

6.6.1 HIGH ELASTICITY OFFERED BY GELATIN-BASED HEMOSTATS TO BOOST DEMAND

TABLE 27 MAJOR PRODUCTS IN GELATIN-BASED MARKET

TABLE 28 GELATIN-BASED MARKET, BY REGION, 2018–2021 (USD MILLION)

TABLE 29 GELATIN-BASED MARKET, BY REGION, 2022–2028 (USD MILLION)

6.7 COLLAGEN-BASED HEMOSTATS

6.7.1 LOW COST AND REDUCED RISK OF DISEASE TRANSMISSION TO PROMOTE ADOPTION OF COLLAGEN-BASED HEMOSTATS

TABLE 30 MAJOR PRODUCTS IN COLLAGEN-BASED MARKET

TABLE 31 COLLAGEN-BASED MARKET, BY REGION, 2018–2021 (USD MILLION)

TABLE 32 COLLAGEN-BASED MARKET, BY REGION, 2022–2028 (USD MILLION)

6.8 OTHER HEMOSTATS

TABLE 33 OTHER MARKET, BY REGION, 2018–2021 (USD MILLION)

TABLE 34 OTHER MARKET, BY REGION, 2022–2028 (USD MILLION)

7 HEMOSTATS MARKET, BY FORMULATION (Page No. - 81)

7.1 INTRODUCTION

TABLE 35 HEMOSTATS INDUSTRY, BY FORMULATION, 2018–2021 (USD MILLION)

TABLE 36 MARKET, BY FORMULATION, 2022–2028 (USD MILLION)

7.2 MATRIX & GEL HEMOSTATS

7.2.1 ABILITY OF MATRIX & GEL HEMOSTATS TO ENHANCE PLATELET AGGREGATION TO BOOST MARKET

TABLE 37 MATRIX & GEL MARKET, BY REGION, 2018–2021 (USD MILLION)

TABLE 38 MATRIX & GEL MARKET, BY REGION, 2022–2028 (USD MILLION)

7.3 SHEET & PAD HEMOSTATS

7.3.1 ABILITY TO CUT SHEET & PAD HEMOSTATS INTO ANY SHAPE OR SIZE TO FUEL ADOPTION

TABLE 39 SHEET & PAD MARKET, BY REGION, 2018–2021 (USD MILLION)

TABLE 40 SHEET & PAD MARKET, BY REGION, 2022–2028 (USD MILLION)

7.4 SPONGE HEMOSTATS

7.4.1 GROWING ACCEPTANCE OF SPONGE HEMOSTATS TO FUEL UPTAKE

TABLE 41 SPONGE MARKET, BY REGION, 2018–2021 (USD MILLION)

TABLE 42 SPONGE MARKET, BY REGION, 2022–2028 (USD MILLION)

7.5 POWDER HEMOSTATS

7.5.1 ABILITY TO SPRAY POWDER FORMULATIONS DIRECTLY ON WOUNDS TO FUEL DEMAND

TABLE 43 POWDER MARKET, BY REGION, 2018–2021 (USD MILLION)

TABLE 44 POWDER MARKET, BY REGION, 2022–2028 (USD MILLION)

8 HEMOSTATS MARKET, BY APPLICATION (Page No. - 88)

8.1 INTRODUCTION

TABLE 45 HEMOSTATS INDUSTRY, BY APPLICATION, 2018–2021 (USD MILLION)

TABLE 46 MARKET, BY APPLICATION, 2022–2028 (USD MILLION)

8.2 PRIMARY NOTES

8.2.1 KEY PRIMARY INSIGHTS

8.3 ORTHOPEDIC SURGERY

8.3.1 INCREASING INCIDENCE OF SPORTS INJURIES TO SUPPORT MARKET GROWTH

TABLE 47 NUMBER OF KNEE & HIP REPLACEMENTS, 2021

TABLE 48 MARKET FOR ORTHOPEDIC SURGERY, BY REGION, 2018–2021 (USD MILLION)

TABLE 49 MARKET FOR ORTHOPEDIC SURGERY, BY REGION, 2022–2028 (USD MILLION)

8.4 GENERAL SURGERY

8.4.1 INCREASING NUMBER OF HERNIA REPAIR PROCEDURES TO DRIVE GROWTH

TABLE 50 TOTAL NUMBER OF INGUINAL HERNIA REPAIR PROCEDURES, 2021

TABLE 51 MARKET FOR GENERAL SURGERY, BY REGION, 2018–2021 (USD MILLION)

TABLE 52 MARKET FOR GENERAL SURGERY, BY REGION, 2022–2028 (USD MILLION)

8.5 NEUROLOGICAL SURGERY

8.5.1 GROWING PREVALENCE OF NEUROLOGICAL DISORDERS TO DRIVE MARKET GROWTH

TABLE 53 MARKET FOR NEUROLOGICAL SURGERY, BY REGION, 2018–2021 (USD MILLION)

TABLE 54 MARKET FOR NEUROLOGICAL SURGERY, BY REGION, 2022–2028 (USD MILLION)

8.6 CARDIOVASCULAR SURGERY

8.6.1 RISING PREVALENCE OF CVD TO DRIVE ADOPTION OF HEMOSTATS

TABLE 55 MARKET FOR CARDIOVASCULAR SURGERY, BY REGION, 2018–2021 (USD MILLION)

TABLE 56 MARKET FOR CARDIOVASCULAR SURGERY, BY REGION, 2022–2028 (USD MILLION)

8.7 RECONSTRUCTIVE SURGERY

8.7.1 GROWING NUMBER OF COSMETIC SURGERIES TO SUPPORT MARKET GROWTH

TABLE 57 MARKET FOR RECONSTRUCTIVE SURGERY, BY REGION, 2018–2021 (USD MILLION)

TABLE 58 MARKET FOR RECONSTRUCTIVE SURGERY, BY REGION, 2022–2028 (USD MILLION)

8.8 GYNECOLOGICAL SURGERY

8.8.1 GROWING USE OF HEMOSTATS IN C-SECTION PROCEDURES TO CONTROL SURGICAL BLEEDING TO SUPPORT GROWTH

TABLE 59 MARKET FOR GYNECOLOGICAL SURGERY, BY REGION, 2018–2021 (USD MILLION)

TABLE 60 MARKET FOR GYNECOLOGICAL SURGERY, BY REGION, 2022–2028 (USD MILLION)

8.9 OTHER SURGICAL APPLICATIONS

TABLE 61 MARKET FOR OTHER SURGICAL APPLICATIONS, BY REGION, 2018–2021 (USD MILLION)

TABLE 62 MARKET FOR OTHER SURGICAL APPLICATIONS, BY REGION, 2022–2028 (USD MILLION)

9 HEMOSTATS MARKET, BY REGION (Page No. - 101)

9.1 INTRODUCTION

TABLE 63 HEMOSTATS INDUSTRY, BY REGION, 2018–2021 (USD MILLION)

TABLE 64 MARKET, BY REGION, 2022–2028 (USD MILLION)

9.2 NORTH AMERICA

FIGURE 26 NORTH AMERICA: HEMOSTATS MARKET SNAPSHOT

TABLE 65 NORTH AMERICA: MARKET, BY COUNTRY, 2018–2021 (USD MILLION)

TABLE 66 NORTH AMERICA: MARKET, BY COUNTRY, 2022–2028 (USD MILLION)

TABLE 67 NORTH AMERICA: MARKET, BY TYPE, 2018–2021 (USD MILLION)

TABLE 68 NORTH AMERICA: MARKET, BY TYPE, 2022–2028 (USD MILLION)

TABLE 69 NORTH AMERICA: MARKET, BY FORMULATION, 2018–2021 (USD MILLION)

TABLE 70 NORTH AMERICA: MARKET, BY FORMULATION, 2022–2028 (USD MILLION)

TABLE 71 NORTH AMERICA: MARKET, BY APPLICATION, 2018–2021 (USD MILLION)

TABLE 72 NORTH AMERICA: MARKET, BY APPLICATION, 2022–2028 (USD MILLION)

9.2.1 NORTH AMERICA: RECESSION IMPACT

9.2.2 US

9.2.2.1 Strong healthcare infrastructure to support uptake of hemostats

TABLE 73 US: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)

TABLE 74 US: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)

9.2.3 CANADA

9.2.3.1 Growing geriatric population and increasing volume of surgeries to drive demand for hemostats

TABLE 75 SURGICAL PROCEDURES PERFORMED IN CANADA, 2021

TABLE 76 CANADA: KEY MACROINDICATORS

TABLE 77 CANADA: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)

TABLE 78 CANADA: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)

9.3 EUROPE

TABLE 79 EUROPE: HEMOSTATS MARKET, BY COUNTRY, 2018–2021 (USD MILLION)

TABLE 80 EUROPE: MARKET, BY COUNTRY, 2022–2028 (USD MILLION)

TABLE 81 EUROPE: MARKET, BY TYPE, 2018–2021 (USD MILLION)

TABLE 82 EUROPE: MARKET, BY TYPE, 2022–2028 (USD MILLION)

TABLE 83 EUROPE: MARKET, BY FORMULATION, 2018–2021 (USD MILLION)

TABLE 84 EUROPE: MARKET, BY FORMULATION, 2022–2028 (USD MILLION)

TABLE 85 EUROPE: MARKET, BY APPLICATION, 2018–2021 (USD MILLION)

TABLE 86 EUROPE: MARKET, BY APPLICATION, 2022–2028 (USD MILLION)

9.3.1 EUROPE: RECESSION IMPACT

9.3.2 GERMANY

9.3.2.1 High healthcare expenditure in Germany to favor market growth

TABLE 87 SURGICAL PROCEDURES PERFORMED IN GERMANY, 2021

TABLE 88 GERMANY: KEY MACROINDICATORS

TABLE 89 GERMANY: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)

TABLE 90 GERMANY: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)

9.3.3 UK

9.3.3.1 Growing volume of hernia repair and cardiovascular surgeries to drive market growth

TABLE 91 SURGICAL PROCEDURES PERFORMED IN UK, 2021

TABLE 92 UK: KEY MACROINDICATORS

TABLE 93 UK: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)

TABLE 94 UK: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)

9.3.4 FRANCE

9.3.4.1 Presence of well-established healthcare system to propel market growth

TABLE 95 SURGICAL PROCEDURES PERFORMED IN FRANCE, 2021

TABLE 96 FRANCE: KEY MACROINDICATORS

TABLE 97 FRANCE: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)

TABLE 98 FRANCE: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)

9.3.5 ITALY

9.3.5.1 Increasing volume of surgeries to drive demand for hemostats

TABLE 99 SURGICAL PROCEDURES PERFORMED IN ITALY, 2021

TABLE 100 ITALY: KEY MACROINDICATORS

TABLE 101 ITALY: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)

TABLE 102 ITALY: MARKET, BY TYPE, 2022–2028 (USD MILLION)

9.3.6 SPAIN

9.3.6.1 Growing healthcare budget and rising efforts to boost local manufacturing of medical products to drive market growth

TABLE 103 SURGICAL PROCEDURES PERFORMED IN SPAIN, 2021

TABLE 104 SPAIN: KEY MACROINDICATORS

TABLE 105 SPAIN: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)

TABLE 106 SPAIN: MARKET, BY TYPE, 2022–2028 (USD MILLION)

9.3.7 RUSSIA

9.3.7.1 Long-term healthcare investment initiatives by government to support market growth

TABLE 107 RUSSIA: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)

TABLE 108 RUSSIA: MARKET, BY TYPE, 2022–2028 (USD MILLION)

9.3.8 SWITZERLAND

9.3.8.1 Increasing public health insurance coverage to drive number of surgical procedures

TABLE 109 SURGICAL PROCEDURES PERFORMED IN SWITZERLAND, 2021

TABLE 110 SWITZERLAND: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)

TABLE 111 SWITZERLAND: MARKET, BY TYPE, 2022–2028 (USD MILLION)

9.3.9 BELGIUM

9.3.9.1 Increasing demand for value-based healthcare services to drive market growth

TABLE 112 SURGICAL PROCEDURES PERFORMED IN BELGIUM, 2021

TABLE 113 BELGIUM: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)

TABLE 114 BELGIUM: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)

9.3.10 REST OF EUROPE

TABLE 115 REST OF EUROPE: PERCENTAGE OF GDP ON HEALTHCARE EXPENDITURE, BY COUNTRY

TABLE 116 REST OF EUROPE: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)

TABLE 117 REST OF EUROPE: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)

9.4 ASIA PACIFIC

FIGURE 27 ASIA PACIFIC: HEMOSTATS MARKET SNAPSHOT

TABLE 118 ASIA PACIFIC: MARKET, BY COUNTRY, 2018–2021 (USD MILLION)

TABLE 119 ASIA PACIFIC: MARKET, BY COUNTRY, 2022–2028 (USD MILLION)

TABLE 120 ASIA PACIFIC: MARKET, BY TYPE, 2018–2021 (USD MILLION)

TABLE 121 ASIA PACIFIC: MARKET, BY TYPE, 2022–2028 (USD MILLION)

TABLE 122 ASIA PACIFIC: MARKET, BY FORMULATION, 2018–2021 (USD MILLION)

TABLE 123 ASIA PACIFIC: MARKET, BY FORMULATION, 2022–2028 (USD MILLION)

TABLE 124 ASIA PACIFIC: MARKET, BY APPLICATION, 2018–2021 (USD MILLION)

TABLE 125 ASIA PACIFIC: MARKET, BY APPLICATION, 2022–2028 (USD MILLION)

9.4.1 ASIA PACIFIC: RECESSION IMPACT

9.4.2 CHINA

9.4.2.1 Growing number of hospitals and healthcare policy reforms to drive growth

TABLE 126 CHINA: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)

TABLE 127 CHINA: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)

9.4.3 JAPAN

9.4.3.1 Strong healthcare system and rising geriatric population to support market growth

TABLE 128 JAPAN: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)

TABLE 129 JAPAN: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)

9.4.4 INDIA

9.4.4.1 Rising healthcare awareness and favorable government support to propel market growth

TABLE 130 INDIA: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)

TABLE 131 INDIA: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)

9.4.5 AUSTRALIA

9.4.5.1 Rising prevalence of chronic diseases to drive market growth

TABLE 132 AUSTRALIA: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)

TABLE 133 AUSTRALIA: MARKET, BY TYPE, 2022–2028 (USD MILLION)

9.4.6 SOUTH KOREA

9.4.6.1 Growing number of cosmetic surgeries to drive demand for hemostats

TABLE 134 SURGICAL PROCEDURES IN SOUTH KOREA, 2021

TABLE 135 SOUTH KOREA: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)

TABLE 136 SOUTH KOREA: MARKET, BY TYPE, 2022–2028 (USD MILLION)

9.4.7 SINGAPORE

9.4.7.1 Government initiatives to promote healthcare services to support market growth

TABLE 137 SINGAPORE: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)

TABLE 138 SINGAPORE: MARKET, BY TYPE, 2022–2028 (USD MILLION)

9.4.8 NEW ZEALAND

9.4.8.1 Increasing number of hip fractures to propel market growth

TABLE 139 NEW ZEALAND: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)

TABLE 140 NEW ZEALAND: MARKET, BY TYPE, 2022–2028 (USD MILLION)

9.4.9 INDONESIA

9.4.9.1 Lucrative growth opportunities for players to boost market

TABLE 141 INDONESIA: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)

TABLE 142 INDONESIA: MARKET, BY TYPE, 2022–2028 (USD MILLION)

9.4.10 MALAYSIA

9.4.10.1 Low healthcare costs, modern medical technology, and highly qualified doctors to favor market growth

TABLE 143 MALAYSIA: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)

TABLE 144 MALAYSIA: MARKET, BY TYPE, 2022–2028 (USD MILLION)

9.4.11 REST OF ASIA PACIFIC

TABLE 145 REST OF ASIA PACIFIC: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)

TABLE 146 REST OF ASIA PACIFIC: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)

9.5 LATIN AMERICA

TABLE 147 LATIN AMERICA: HEMOSTATS MARKET, BY COUNTRY, 2018–2021 (USD MILLION)

TABLE 148 LATIN AMERICA: MARKET, BY COUNTRY, 2022–2028 (USD MILLION)

TABLE 149 LATIN AMERICA: MARKET, BY TYPE, 2018–2021 (USD MILLION)

TABLE 150 LATIN AMERICA: MARKET, BY TYPE, 2022–2028 (USD MILLION)

TABLE 151 LATIN AMERICA: MARKET, BY FORMULATION, 2018–2021 (USD MILLION)

TABLE 152 LATIN AMERICA: MARKET, BY FORMULATION, 2022–2028 (USD MILLION)

TABLE 153 LATIN AMERICA: MARKET, BY APPLICATION, 2018–2021 (USD MILLION)

TABLE 154 LATIN AMERICA: MARKET, BY APPLICATION, 2022–2028 (USD MILLION)

9.5.1 LATIN AMERICA: RECESSION IMPACT

9.5.2 BRAZIL

9.5.2.1 Brazil to dominate Latin American market for hemostats

TABLE 155 BRAZIL: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)

TABLE 156 BRAZIL: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)

9.5.3 MEXICO

9.5.3.1 Low-cost surgeries to drive medical tourism in Mexico

TABLE 157 MEXICO: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)

TABLE 158 MEXICO: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)

9.5.4 REST OF LATIN AMERICA

TABLE 159 REST OF LATIN AMERICA: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)

TABLE 160 REST OF LATIN AMERICA: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION)

9.6 MIDDLE EAST & AFRICA

9.6.1 STRENGTHENING OF HEALTHCARE INFRASTRUCTURE TO SUPPORT MARKET GROWTH

TABLE 161 MIDDLE EAST & AFRICA: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION)

TABLE 162 MIDDLE EAST & AFRICA: MARKET, BY TYPE, 2022–2028 (USD MILLION)

TABLE 163 MIDDLE EAST & AFRICA: MARKET, BY FORMULATION, 2018–2021 (USD MILLION)

TABLE 164 MIDDLE EAST & AFRICA: MARKET, BY FORMULATION, 2022–2028 (USD MILLION)

TABLE 165 MIDDLE EAST & AFRICA: MARKET, BY APPLICATION, 2018–2021 (USD MILLION)

TABLE 166 MIDDLE EAST & AFRICA: MARKET, BY APPLICATION, 2022–2028 (USD MILLION)

9.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT

10 COMPETITIVE LANDSCAPE (Page No. - 161)

10.1 OVERVIEW

10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN

10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN HEMOSTATS MARKET

TABLE 167 OVERVIEW OF STRATEGIES DEPLOYED BY KEY HEMOSTAT MANUFACTURING COMPANIES

10.3 REVENUE ANALYSIS

FIGURE 28 REVENUE ANALYSIS OF TOP PLAYERS IN HEMOSTATS INDUSTRY (2018–2022)

10.4 MARKET SHARE ANALYSIS

FIGURE 29 MARKET SHARE ANALYSIS OF TOP PLAYERS IN HEMOSTATS INDUSTRY (2022)

TABLE 168 HEMOSTATS INDUSTRY: DEGREE OF COMPETITION

10.5 COMPANY EVALUATION MATRIX

10.5.1 LIST OF EVALUATED VENDORS

10.5.2 STARS

10.5.3 EMERGING LEADERS

10.5.4 PERVASIVE PLAYERS

10.5.5 PARTICIPANTS

FIGURE 30 HEMOSTATS INDUSTRY: COMPANY EVALUATION MATRIX (2022)

10.5.6 COMPANY FOOTPRINT

10.5.6.1 Product & regional footprint analysis

FIGURE 31 PRODUCT AND REGIONAL FOOTPRINT ANALYSIS OF TOP PLAYERS IN HEMOSTATS INDUSTRY

TABLE 169 HEMOSTATS INDUSTRY: COMPETITIVE BENCHMARKING OF KEY PLAYERS

TABLE 170 COMPANY FOOTPRINT, BY TYPE

TABLE 171 COMPANY FOOTPRINT, BY REGION

10.6 START-UP/SME EVALUATION MATRIX

10.6.1 PROGRESSIVE COMPANIES

10.6.2 RESPONSIVE COMPANIES

10.6.3 DYNAMIC COMPANIES

10.6.4 STARTING BLOCKS

FIGURE 32 HEMOSTATS MARKET: START-UP/SME EVALUATION MATRIX (2022)

10.7 COMPETITIVE SCENARIO

10.7.1 PRODUCT LAUNCHES & APPROVALS

TABLE 172 KEY PRODUCT LAUNCHES & APPROVALS (JANUARY 2018–OCTOBER 2023)

10.7.2 DEALS

TABLE 173 KEY DEALS (JANUARY 2018–OCTOBER 2023)

10.7.3 OTHER KEY DEVELOPMENTS

TABLE 174 OTHER KEY DEVELOPMENTS (JANUARY 2018–OCTOBER 2023)

11 COMPANY PROFILES (Page No. - 174)

(Business overview, Products offered, Recent developments & MnM View)*

11.1 KEY PLAYERS

11.1.1 JOHNSON & JOHNSON

TABLE 175 JOHNSON & JOHNSON: BUSINESS OVERVIEW

FIGURE 33 JOHNSON & JOHNSON: COMPANY SNAPSHOT (2022)

11.1.2 BAXTER INTERNATIONAL

TABLE 176 BAXTER INTERNATIONAL: BUSINESS OVERVIEW

FIGURE 34 BAXTER INTERNATIONAL: COMPANY SNAPSHOT (2022)

11.1.3 PFIZER INC.

TABLE 177 PFIZER INC.: BUSINESS OVERVIEW

FIGURE 35 PFIZER INC.: COMPANY SNAPSHOT (2022)

11.1.4 B. BRAUN SE

TABLE 178 B. BRAUN SE: BUSINESS OVERVIEW

FIGURE 36 B. BRAUN SE: COMPANY SNAPSHOT (2022)

11.1.5 BECTON, DICKINSON AND COMPANY

TABLE 179 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW

FIGURE 37 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022)

11.1.6 TELEFLEX INCORPORATED

TABLE 180 TELEFLEX INCORPORATED: BUSINESS OVERVIEW

FIGURE 38 TELEFLEX INCORPORATED: COMPANY SNAPSHOT (2022)

11.1.7 MEDTRONIC PLC

TABLE 181 MEDTRONIC PLC: BUSINESS OVERVIEW

FIGURE 39 MEDTRONIC PLC: COMPANY SNAPSHOT (2022)

11.1.8 HEMOSTASIS, LLC

TABLE 182 HEMOSTASIS, LLC: BUSINESS OVERVIEW

11.1.9 STRYKER CORPORATION

TABLE 183 STRYKER CORPORATION: BUSINESS OVERVIEW

FIGURE 40 STRYKER CORPORATION: COMPANY SNAPSHOT (2022)

11.1.10 INTEGRA LIFESCIENCES

TABLE 184 INTEGRA LIFESCIENCES: BUSINESS OVERVIEW

FIGURE 41 INTEGRA LIFESCIENCES: COMPANY SNAPSHOT (2022)

11.1.11 ADVANCED MEDICAL SOLUTIONS GROUP PLC

TABLE 185 ADVANCED MEDICAL SOLUTIONS GROUP PLC: BUSINESS OVERVIEW

FIGURE 42 ADVANCED MEDICAL SOLUTIONS GROUP PLC: COMPANY SNAPSHOT (2022)

11.1.12 SAMYANG HOLDINGS CORPORATION

TABLE 186 SAMYANG CORPORATION: BUSINESS OVERVIEW

FIGURE 43 SAMYANG CORPORATION: COMPANY SNAPSHOT (2022)

*Details on Business overview, Products offered, Recent developments & MnM View might not be captured in case of unlisted companies.

11.2 OTHER PLAYERS

11.2.1 MARINE POLYMER TECHNOLOGIES, INC.

11.2.2 GELITA MEDICAL GMBH

11.2.3 DILON TECHNOLOGIES, INC.

11.2.4 BETATECH MEDICAL

11.2.5 MERIL LIFE SCIENCES PVT. LTD.

11.2.6 BIOCER ENTWICKLUNGS-GMBH

11.2.7 UNILENE

11.2.8 KATSAN MEDICAL DEVICES

11.2.9 TRICOL BIOMEDICAL

11.2.10 3-D MATRIX MEDICAL TECHNOLOGY

11.2.11 HEMOSTAT MEDICAL GMBH

11.2.12 MEDTRADE PRODUCTS LIMITED

11.2.13 ALTAYLAR MEDICAL

12 APPENDIX (Page No. - 215)

12.1 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL

12.2 CUSTOMIZATION OPTIONS

12.3 RELATED REPORTS

12.4 AUTHOR DETAILS

The objective of the study is to analyze the key market dynamics, such as drivers, opportunities, restraints, challenges, and key player strategies. To track company developments such as acquisitions, product launches, expansions, agreements, and partnerships of the leading players, the competitive landscape of the hemostats market to analyze market players on various parameters within the broad categories of business and product strategy. Top-down and bottom-up approaches were used to estimate the market size. To estimate the market size of segments and subsegments, the market breakdown and data triangulation were used.

The four steps involved in estimating the market size are

Secondary Research

In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information as well as assess prospects.

The following is a breakdown of the primary respondents:

Breakdown of Primary Participants:

Hemostats Market Size, and Share

Note 1: Others include sales managers, marketing managers, and product managers.

Note 2: Companies are classified into tiers based on their total revenues. As of 2022, Tier 1 = >USD 100 million, Tier 2 = USD 10 million to USD 100 million, and Tier 3 = <USD 10 million.

To know about the assumptions considered for the study, download the pdf brochure

COMPANY NAME	DESIGNATION
Johnson & Johnson	Regional Manager
Baxter International	Senior Product Manager
Meril Life Sciences	Marketing Manager

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the hemostats market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

The key players in the industry have been identified through extensive secondary research
The revenues generated by leading players operating in the hemostats market have been determined through primary and secondary research.
All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

Global Hemostats Market Size: Bottom Up Approach

Hemostats Market Size, and Share

To know about the assumptions considered for the study, Request for Free Sample Report

Global Hemostats Market Size: Top-Down Approach

Hemostats Market Size, and Share

Data Triangulation

After arriving at the overall market size by applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Market Definition

When a blood vessel is damaged during surgery, the resulting blood loss must be stopped immediately. The process of stopping this bleeding is called hemostasis. Hemostats provide a temporary block by forming blood clots to control bleeding. The use of hemostats must be quick, localized, and carefully regulated. Hemostats are primarily required when the bleeding is heavy or the patient is suffering from congenital diseases or trauma defects.

Key Stakeholders

Senior Management
End User
Finance/Procurement Department
R&D Department

Report Objectives

To define, describe, and forecast the hemostats market by type, formulation, application, and region
To forecast the size of the hemostats market with respect to five regional segments: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
To provide detailed information regarding the major factors influencing the market growth (drivers, restraints, opportunities, and challenges)
To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall hemostats market
To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
To profile the key players in the hemostats market and comprehensively analyze their market shares and core competencies in terms of market developments and growth strategies
To track and analyze competitive developments such as product launches, agreements, collaborations, partnerships, and acquisitions in the hemostats market
To benchmark players within the hemostats market using the Company Evaluation Matrix framework, which analyzes market players on various parameters within the broad categories of business strategy, market share, and product offerings

Available Customizations

MarketsandMarkets offers the following customizations for this market report.

Country Information

Additional country-level analysis of the hemostats market

Company profiles

Additional five company profiles of players operating in the hemostats market.

Product Analysis

Product matrix, which provides a detailed comparison of the product portfolio of each company in the hemostats market

Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.